Substance P 1-9

Substance P 1-9 is a peptide fragment derived from the N-terminal sequence of the neuropeptide Substance P, a member of the tachykinin family widely recognized for its role in neurotransmission and neurogenic inflammation. As a truncated analog, Substance P 1-9 retains the initial nine amino acids of the full-length peptide, offering researchers a valuable tool to dissect the structure-activity relationships and receptor interactions of Substance P and related peptides. Its unique sequence facilitates the investigation of specific binding domains, signaling mechanisms, and functional properties distinct from those of the intact neuropeptide, thereby enhancing the understanding of peptide-mediated physiological processes in both central and peripheral systems.

Receptor binding studies: Researchers frequently employ the N-terminal fragment of Substance P in receptor binding assays to elucidate the specificity and affinity of neurokinin receptors, particularly NK1 and related subtypes. By comparing the binding characteristics of Substance P 1-9 with full-length and other truncated peptides, investigators can identify critical residues involved in receptor recognition and activation. Such studies are essential for mapping ligand-receptor interactions and for the rational design of selective agonists or antagonists targeting neurokinin pathways.

Peptide structure-activity relationship analysis: The fragment's defined sequence allows for detailed structure-activity relationship (SAR) investigations, enabling scientists to pinpoint which amino acid residues contribute to biological activity or receptor selectivity. By systematically modifying or substituting residues within Substance P 1-9, researchers can assess how these changes impact peptide conformation, receptor engagement, and downstream signaling. These SAR studies are instrumental in guiding the design of novel peptide analogs with tailored pharmacological profiles.

Neuropeptide signaling pathway exploration: Substance P 1-9 serves as a model substrate for studying the intracellular signaling cascades initiated by tachykinin peptides. Its use in cell-based assays or in vitro systems provides insights into the activation of second messenger systems, such as phospholipase C or protein kinase pathways, and helps clarify the minimal structural requirements for eliciting specific cellular responses. Such mechanistic studies are valuable for unraveling the complexities of neuropeptide-mediated communication in neuronal and non-neuronal tissues.

Peptide degradation and metabolic profiling: The stability and metabolic fate of neuropeptide fragments are of significant interest in biochemical research. Substance P 1-9 is utilized in enzymatic degradation assays to characterize the action of peptidases and proteases that regulate peptide turnover in biological systems. By monitoring its cleavage patterns and degradation kinetics, investigators gain a deeper understanding of the metabolic processing of tachykinin peptides, which has implications for both physiological regulation and peptide-based drug development.

Peptide synthesis method development: As a representative short peptide, Substance P 1-9 is often employed as a model substrate in the optimization and validation of solid-phase peptide synthesis protocols. Its moderate length and well-characterized sequence make it suitable for evaluating coupling efficiencies, resin compatibility, and purification strategies. Methodological advancements achieved using this fragment can be directly translated to the synthesis of more complex peptides, thereby supporting broader peptide research and development initiatives.

1. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

5. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet